NovaBridge Biosciences (NBP) Company Report

Analyst Coverage

Research analysts covering NovaBridge Biosciences.

Recent press releases and 8-K filings for NBP.

NovaBridge Biosciences Reports Positive Givastomig Phase 1b Data for Gastric Cancer

NBP

New Projects/Investments

NovaBridge Biosciences announced positive updated results from its Phase 1b combination study of givastomig (a CLDN18.2 x 4-1BB bispecific antibody) in patients with first-line (1L) HER2-negative, metastatic gastric cancer.
The study demonstrated robust efficacy, with an Objective Response Rate (ORR) of 77% at 8 mg/kg and 73% at 12 mg/kg. The median Progression-Free Survival (PFS) was 16.9 months at 8 mg/kg, and the 6-month PFS rate for the 12 mg/kg cohort was 91%.
The combination treatment was well tolerated, with a safety profile comparable to the current standard of care. Immune-related gastritis, observed in 33% of patients, was notably associated with improved clinical outcomes.
NovaBridge is on track to initiate enrollment in a global, randomized Phase 2 study for givastomig in Q1 2026, positioning it as a potential best-in-class CLDN18.2 asset in a gastric cancer market projected to reach $12 billion by 2030.

Jan 6, 2026, 12:00 PM

NovaBridge Biosciences Announces Q3 2025 Developments and Financials

NBP

New Projects/Investments

Earnings

M&A

NovaBridge Biosciences (formerly I-Mab) completed a rebranding and business model update in October 2025, transitioning to a biotechnology platform company, and filed an application on October 31, 2025, for a proposed dual primary listing on the Hong Kong Stock Exchange.
For the nine months ended September 30, 2025, the company reported no revenue and a net loss from continuing operations of $15.482 million, a significant decrease from $38.852 million in the prior year period. This improvement was driven by a 54.0% reduction in research and development expenses to $7.2 million and a 36.7% decrease in administrative expenses to $14.1 million.
The company strengthened its liquidity with net proceeds of approximately $61.2 million from an underwritten offering completed on August 1, 2025. As of September 30, 2025, cash and cash equivalents totaled $228.1 million, which is expected to be sufficient for at least the next 12 months.
The divestiture of its Greater China assets and business operations was completed on April 2, 2024, for an aggregate consideration of up to $80 million, contingent on future milestones, and the company ceased consolidating these operations from the second quarter of 2024.

Dec 18, 2025, 1:30 PM

NovaBridge Biosciences Presents Positive Ragistomig Phase 1 Dose Expansion Data

NBP

New Projects/Investments

NovaBridge Biosciences presented new data from the expanded 3mg/kg every 6 week (Q6W) Phase 1 dosing study for ragistomig, a bispecific 4-1BB X PD-L1 antibody, at the European Society for Medical Oncology – Immuno-Oncology Congress 2025 (ESMO-IO 2025).
The new Q6W dosing interval demonstrated comparable anti-tumor efficacy and a significantly improved safety profile compared to the prior Q2W schedule.
Specifically, only 5% of patients experienced ≥ Grade 3 liver function elevation with the Q6W regimen, a notable improvement from 40% with the Q2W regimen.
These positive results support the advancement of ragistomig into combination studies.

Dec 10, 2025, 9:37 PM

NovaBridge Announces Presentation of Ragistomig Phase 1 Data at ESMO-IO

NBP

New Projects/Investments

NovaBridge Biosciences announced that new data from the expanded Phase 1 dosing study for ragistomig, a 4-1BB X PD-L1 bispecific antibody, will be presented at the European Society for Medical Oncology – Immuno-Oncology Congress 2025 (ESMO-IO 2025) on December 10, 2025.
The Phase 1 study successfully defined a new Q6W extended dosing interval for ragistomig, which produced strong anti-tumor efficacy in PD-L1-non-responders with an improved safety profile.
These interim results, including immunological data, support the progression to combination studies for ragistomig, a drug designed to treat patients who are relapsed or refractory to checkpoint inhibitors.

Dec 4, 2025, 12:06 PM